Sinomenine, a COX-2 inhibitor, induces cell cycle arrest and inhibits growth of human colon carcinoma cells in vitro and in vivo

Yang,Haibo; Yin,Peihao; Shi,Zhan; Ma,Yanchun; Zhao,Chenggen; Zheng,Jampu; Chen,Teng

doi:10.3892/ol.2015.3838

Sinomenine, a COX-2 inhibitor, induces cell cycle arrest and inhibits growth of human colon carcinoma cells in vitro and in vivo

Authors:
- Haibo Yang
- Peihao Yin
- Zhan Shi
- Yanchun Ma
- Chenggen Zhao
- Jampu Zheng
- Teng Chen
View Affiliations

Affiliations: Department of Colorectal Surgery, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, P.R. China, Department of General Surgery, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, P.R. China, Experimental Center, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, P.R. China, Department of Oncology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, P.R. China
Published online on: October 29, 2015 https://doi.org/10.3892/ol.2015.3838
Pages: 411-418

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Certain non-steroidal anti-inflammatory drugs may possess anti-tumorigenic effects in certain cancer cell types. Sinomenine (SIN) is an alkaloid from Sinomenium acutum, a Chinese medicinal plant that inhibits inflammatory reactions and that has been used in the treatment of neuralgia and rheumatic diseases. In this study, we investigated the anticancer effects of SIN against colorectal cancer in vitro and in vivo, as well as the underlying mechanisms. The effects of SIN on proliferation, cell cycle progression and cyclooxygenase (COX)‑2 expression were examined in human colorectal cancer‑derived SW1116 cells. The in vivo effects of SIN were examined in a model of SW1116 tumor xenograft growth in athymic nude mice. Changes in COX‑2 expression induced by the biological effects of SIN were analyzed by western blot analysis. The effects of SIN treatment on G1 phase cell cycle regulators in xenografts were analyzed by immunohistochemistry. Our findings demonstrate that SIN inhibits the proliferation of SW1116 cells by promoting their accumulation in the G1 phase, with concomitant suppression of COX‑2 expression. Time‑ and dose‑dependent inhibition of tumor growth and reduced toxicity were observed in nude mice administered daily intraperitoneal injections of SIN at doses of 25, 50 and 100 mg/kg. SIN‑treated tumors also exhibited reduced COX‑2 expression, a marked increase in Cip1/p21 protein levels and a decrease in the levels of cyclin D1 and cyclin E. SIN may be an effective chemopreventive agent against colorectal cancer. The growth inhibitory properties of SIN against colorectal cancer may be mediated via a COX‑2 inhibitory effect and cell cycle arrest in the G1 phase.

View Figures

View References

1	Ekberg M, Callender M, Hamer H and Rogers S: Exploring the decision to participate in the national health service bowel cancer screening programme. Eur J Cancer Prev. 23:391–397. 2014. View Article : Google Scholar : PubMed/NCBI
2	Hou L, Jiang J, Liu B, Nasca PC, Wu Y, Zou X, Han W, Chen Y, Zhang B, Xue F, et al: Association between smoking and deaths due to colorectal malignant carcinoma: a national population-based case-control study in China. Br J Cancer. 110:1351–1358. 2014. View Article : Google Scholar : PubMed/NCBI
3	Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer. 94:153–156. 2001. View Article : Google Scholar : PubMed/NCBI
4	Chatenoud L, Bertuccio P, Bosetti C, Malvezzi M, Levi F, Negri E and La Vecchia C: Trends in mortality from major cancers in the Americas: 1980–2010. Ann Oncol. 25:1843–1853. 2014. View Article : Google Scholar : PubMed/NCBI
5	Zaniboni A and Labianca R: Gruppo Italiano per lo Studio e la Cura dei Tumori del Digerente: Adjuvant therapy for stage II colon cancer: an elephant in the living room? Ann Oncol. 15:1310–1318. 2004. View Article : Google Scholar : PubMed/NCBI
6	Rao S and Cunningham D: Adjuvant therapy for colon cancer in the new millenium. Scand J Surg. 92:57–64. 2003.PubMed/NCBI
7	Sinha VR and Honey C: Critical aspects in rationale design of fluorouracil-based adjuvant therapies for the management of colon cancer. Crit Rev Ther Drug Carrier Syst. 29:89–148. 2012. View Article : Google Scholar : PubMed/NCBI
8	Lotfi-Jam K, Carey M, Jefford M, Schofield P, Charleson C and Aranda S: Nonpharmacologic strategies for managing common chemotherapy adverse effects: a systematic review. J Clin Oncol. 26:5618–5629. 2008. View Article : Google Scholar : PubMed/NCBI
9	Latimer N, Lord J, Grant RL, O'Mahony R, Dickson J and Conaghan PG: Value of information in the osteoarthritis setting: Cost effectiveness of COX-2 selective inhibitors, traditional NSAIDs and proton pump inhibitors. Pharmacoeconomics. 29:225–237. 2011. View Article : Google Scholar : PubMed/NCBI
10	Jacobo-Herrera NJ, Pérez-Plasencia C, Camacho-Zavala E, González GF, Urrutia EL, García-Castillo V and Zentella-Dehesa A: Clinical evidence of the relationship between aspirin and breast cancer risk (review). Oncol Rep. 32:4512014.PubMed/NCBI
11	Brasky TM, Liu J, White E, et al: Non-steroidal anti-inflammatory drugs and cancer risk in women: results from the Women's Health Initiative. Int J Cancer. 135:1869–1883. 2014. View Article : Google Scholar : PubMed/NCBI
12	Wu X, Cai M, Ji F and Lou LM: The impact of COX-2 on invasion of osteosarcoma cell and its mechanism of regulation. Cancer Cell Int. 14:272014. View Article : Google Scholar : PubMed/NCBI
13	Liggett JL, Zhang X, Eling TE and Baek SJ: Anti-tumor activity of non-steroidal anti-inflammatory drugs: cyclooxygenase-independent targets. Cancer Lett. 346:217–224. 2014. View Article : Google Scholar : PubMed/NCBI
14	Davies NM and Jamali F: COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. J Pharm Pharm Sci. 7:332–336. 2004.PubMed/NCBI
15	Zhang MF, Zhao Y, Jiang KY, et al: Comparative pharmacokinetics study of sinomenine in rats after oral dministration of sinomenine monomer and sinomenium acutum extract. Molecules. 19:12065–12077. 2014. View Article : Google Scholar : PubMed/NCBI
16	Gao T, Hao J, Wiesenfeld-Hallin Z, et al: Analgesic effect of sinomenine in rodents after inflammation and nerve injury. Eur J Pharmacol. 721:5–11. 2013. View Article : Google Scholar : PubMed/NCBI
17	Mo ZX, An SL and Zhou JY: Effects of caulis sinomenii and sinomenine on morphine-induced place preference and brain histamine level in mice. Nan Fang Yi Ke Da Xue Xue Bao. 26:1709–1713. 2006.(In Chinese). PubMed/NCBI
18	Yamasaki H: Pharmacology of sinomenine, an anti-rheumatic alkaloid from sinomenium acutum. Acta Med Okayama. 30:1–20. 1976.PubMed/NCBI
19	Candinas D, Mark W, Kaever V, et al: Immunomodulatory effects of the alkaloid sinomenine in the high responder ACI-to-Lewis cardiac allograft model. Transplantation. 62:1855–1860. 1996. View Article : Google Scholar : PubMed/NCBI
20	Jiang T, Zhou L, Zhang W, Qu D, Xu X, Yang Y and Li S: Effects of sinomenine on proliferation and apoptosis in human lung cancer cell line NCI-H460 in vitro. Mol Med Rep. 3:51–56. 2010.PubMed/NCBI
21	Zhou L, Luan H, Liu Q, Jiang T, Liang H, Dong X and Shang H: Activation of PI3K/Akt and ERK signaling pathways antagonized sinomenine-induced lung cancer cell apoptosis. Mol Med Rep. 5:1256–1260. 2012.PubMed/NCBI
22	Kues WA, Anger M, Carnwath JW, et al: Cell cycle synchronization of porcine fetal fibroblasts: effects of serum deprivation and reversible cell cycle inhibitors. Biol Reprod. 62:412–419. 2000. View Article : Google Scholar : PubMed/NCBI
23	Chen M, Huang J, Yang X, et al: Serum starvation induced cell cycle synchronization facilitates human somatic cells reprogramming. PLoS One. 7:e282032012. View Article : Google Scholar : PubMed/NCBI
24	Tan Y, Sun X, Xu M, et al: Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice. Clin Cancer Res. 5:2157–2163. 1999.PubMed/NCBI
25	Tjandrawinata RR, Dahiya R and Hughes-Fulford M: Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer. 75:1111–1118. 1997. View Article : Google Scholar : PubMed/NCBI
26	Maekawa M, Sugano K, Sano H, et al: Increased expression of cyclooxygenase-2 to −1 in human colorectal cancers and adenomas, but not in hyperplastic polyps. Jpn J Clin Oncol. 28:421–426. 1998. View Article : Google Scholar : PubMed/NCBI
27	Hao X, Bishop AE, Wallace M, et al: Early expression of cyclo-oxygenase-2 during sporadic colorectal carcinogenesis. J Pathol. 187:295–301. 1999. View Article : Google Scholar : PubMed/NCBI
28	Sheehan KM, Sheahan K, O'Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ and Murray FE: The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA. 282:1254–1257. 1999. View Article : Google Scholar : PubMed/NCBI
29	Kõivomägi M and Skotheim JM: Docking interactions: cell-cycle regulation and beyond. Curr Biol. 24:R647–R649. 2014. View Article : Google Scholar : PubMed/NCBI
30	Dorée M and Hunt T: From Cdc2 to Cdk1: when did the cell cycle kinase join its cyclin partner? J Cell Sci. 115:2461–2464. 2002.PubMed/NCBI
31	Sherr CJ and Roberts JM: Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 18:2699–2711. 2004. View Article : Google Scholar : PubMed/NCBI
32	Fisher D, Krasinska L, Coudreuse D and Novák B: Phosphorylation network dynamics in the control of cell cycle transitions. J Cell Sci. 125:4703–4711. 2012. View Article : Google Scholar : PubMed/NCBI
33	Yoon MK, Mitrea DM, Ou L and Kriwacki RW: Cell cycle regulation by the intrinsically disordered proteins p21 and p27. Biochem Soc Trans. 40:981–988. 2012. View Article : Google Scholar : PubMed/NCBI
34	Weinberg WC and Denning MF: P21Waf1 control of epithelial cell cycle and cell fate. Crit Rev Oral Biol Med. 13:453–464. 2002. View Article : Google Scholar : PubMed/NCBI
35	Shankland SJ and Wolf G: Cell cycle regulatory proteins in renal disease: Role in hypertrophy, proliferation and apoptosis. Am J Physiol Renal Physiol. 278:F515–F529. 2000.PubMed/NCBI
36	Todd R, Hinds PW, Munger K, Rustgi AK, Opitz OG, Suliman Y and Wong DT: Cell cycle dysregulation in oral cancer. Crit Rev Oral Bio Med. 13:51–61. 2002. View Article : Google Scholar
37	Schafer KA: The cell cycle: a review. Vet Pathol. 35:461–478. 1998. View Article : Google Scholar : PubMed/NCBI